Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 Diabetes

NCT00715663 · clinicaltrials.gov ↗

COMPLETED

Status

1584

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2
Delivery Systems

Interventions

DRUG: biphasic insulin aspart 30

Sponsor

Novo Nordisk A/S